Antioxidant defence and oxidative stress markers in cats with asymptomatic and symptomatic hypertrophic cardiomyopathy: a pilot study

Marcin Michalek¹*, Aleksandra Tabiś², Urszula Paslawska¹ and Agnieszka Noszczyk-Nowak¹

Abstract

Background: Hypertrophic cardiomyopathy is the most common cardiovascular cause of death in cats. Although the majority of cats remain asymptomatic, some may develop signs of chronic heart failure due to diastolic failure, arterial thromboembolism (ATE) or sudden cardiac death. Therefore, it is crucial to identify individuals that are in high risk of developing cardiac complications before the onset of life-threatening signs. Oxidative stress is the imbalance between the production and neutralisation of reactive oxygen species. Uncontrolled reactive oxygen species overproduction leads to protein and lipid peroxidation and damages the DNA strands, injuring the cells and leading to their death. The aim of the study was to evaluate the oxidative state in cats with hypertrophic cardiomyopathy and healthy controls.

Results: In total, 30 cats divided into three groups were assessed: animals with clinically evident hypertrophic cardiomyopathy (HCM; n = 8), subclinical hypertrophic cardiomyopathy (SUB-HCM; n = 11) and healthy controls (n = 11). The activity of superoxide dismutase was statistically significantly lower in animals with symptomatic and asymptomatic hypertrophic cardiomyopathy (HCM 0.99 ± 0.35 U/mL; SUB-HCM 1.39 ± 0.4 U/mL) compared to healthy cats (2.07 ± 0.76 U/mL, p < 0.01). The activity of catalase was significantly lower in the SUB-HCM group (19.4 ± 4.2 nmol/min/mL) compared to the HCM (23.6 ± 5.9 nmol/min/mL) and the control (30 ± 7.5 nmol/min/mL, p < 0.01) group. The activity of glutathione peroxidase was 4196 ± 353 nmol/min/mL in the HCM group, 4331 ± 451 nmol/min/mL in the SUB-HCM group and 4037 ± 341 nmol/min/mL in the control group and did not differ significantly between groups. The total antioxidant capacity of plasma was 602 ± 65.5 copper reducing equivalents (CRE) in the HCM group, 605.9 ± 39.9 CRE in the SUB-HCM group and 629 ± 77.5 CRE in the healthy cats and did not differ significantly between the groups.

Conclusions: Activities of superoxide dismutase and catalase differed in cats with hypertrophic cardiomyopathy, however the activity of the latter was only significantly lower in asymptomatic stage of the disease. The potentially beneficial effect of antioxidative substances on the disease progression in the asymptomatic and symptomatic stage of this disease should also be examined.

Keywords: Cardiology, Cats, Hypertrophic cardiomyopathy, Oxidative stress, Antioxidative enzymes
Background
Hypertrophic cardiomyopathy (HCM) is the most common cardiovascular cause of death in cats [1]. The disorder involves symmetric or asymmetric left ventricular myocardial hypertrophy without any underlying risk factors. Although the majority of cats remain asymptomatic, some may develop signs of chronic heart failure due to diastolic failure, arterial thromboembolism (ATE) or sudden cardiac death [2, 3]. A particularly high incidence of hypertrophic cardiomyopathy in breeds such as the Maine Coon [4], Ragdoll [5], British shorthair [6] or Norwegian Forest cat [7] suggest a hereditary nature of the disease. To date, the genetic mutation of the cardiac myosin binding protein-C gene has only been identified in the Maine Coon and Ragdoll [5, 8]. Therefore, it is crucial to identify individuals that are in high risk of developing cardiac complications before the onset of life-threatening signs [9]. In the absence of consensus guidelines on the treatment of feline hypertrophic cardiomyopathy, all the therapeutic decisions are largely an extrapolation from human medicine. Currently, the therapy is aimed at prevention of congestive heart failure, arrhythmias and thromboembolic events [9, 10]. An inhibitor of sarcomere contractility, known as MYK-461, has been proven to inhibit the left ventricular hypertrophy, myocyte disarray and myocardial fibrosis in mice [11]. Thus far, only one report has been published on its efficacy in feline hypertrophic cardiomyopathy, showing its capability to reduce contractility, eliminate systolic anterior motion of the mitral valve and relieve left ventricular outflow tract obstruction [12].

Oxidative stress is the imbalance between the production and neutralisation of reactive oxygen species (ROS) [13]. Uncontrolled ROS overproduction leads to protein and lipid peroxidation and damages the DNA strands, injuring the cells and leading to their death. Living organisms have developed a number of mechanisms aimed at ROS detoxification. The main elements of the enzymatic system of antioxidant protection are superoxide dismutase (SOD) converting the superoxide anion (O2−) into hydrogen peroxide, which is ultimately detoxified by catalase (CAT) and glutathione peroxidase (GPx), with the water molecule as the end product [14]. Oxidative stress can also be determined based on the concentration of peroxidation byproducts. Malondialdehyde (MDA) is a well-known marker of serum lipid peroxidation. Oxygen free radicals have been proven to play a role in the pathogenesis of certain diseases. In such cases, the aim of the therapy is to suppress oxidative stress and the damaging effects of free radicals. It has been proven that supplementation with antioxidative substances may have a positive effect on the course of those diseases, where excessive oxidative stress is associated with its pathogenicity [15]. One proven effect of antioxidants is the attenuation of the pacing-induced atrial remodelling or improvement in the endothelial function in patients with atherosclerosis [16, 17].

In the cardiovascular system, oxidative stress activates pathways responsible for pathological remodelling of the myocardium, impaired systolic function, fibroblast stimulation and the activation of metalloproteinases, which all contribute to chronic heart failure [18]. What is more, ROS can also stimulate cardiac hypertrophy via activation of kinase signalling pathways [19]. There is a paucity of information available in literature regarding oxidative stress in hypertrophic cardiomyopathy. One study showed increased serum levels of 8-isoprostaglandin F2α in human patients with HCM compared to healthy controls and obstructive form of the disease was associated with higher levels of oxidative damage byproducts than non-obstructive subgroup [20]. Interestingly, an experimental study performed on guinea pigs showed, that heart muscle hypertrophy induced by ascending aorta banding is associated with decreased oxidative stress, however transition to heart failure stage was characterized by increased oxidative damage [21]. Only one study focused on feline HCM and an impaired cardiac mitochondrial oxidative phosphorylation capacity and increased mitochondrial ROS release were evidenced [22]. To date, blood parameters of oxidative stress and antioxidant defence mechanisms in the course of feline hypertrophic cardiomyopathy have not been studied.

The aim of the study was to evaluate the oxidative state in cats with hypertrophic cardiomyopathy and healthy controls.

Results
In total, 30 cats were assessed. The mean (± standard deviation) age and weight of the animals was 4.6 ± 2.51 years and 5.36 ± 1.57 kg, respectively. The study population included 23 males, 17 of which were castrated, and seven females, 5 of which were spayed. Eleven healthy cats, with a mean age of 3.63 ± 2.06 years and a mean weight of 5.2 ± 1.54 kg, were included in the control group. That group included five Maine Coons, two European shorthair cats, two British shorthair cats, one ragdoll and one Norwegian forest cat. There were 11 cats in the asymptomatic hypertrophic cardiomyopathy group, nine of which were males. The mean age of the cats in this group was 5.94 ± 2.23 years, while the mean body weight was 4.95 ± 1.13 kg. Three British shorthair cats, two Maine Coons, two Devon Rexes, two European shorthair cats and one Sphinx, Persian and Scottish Fold cats each were included in that group. There were eight cats in the symptomatic hypertrophic cardiomyopathy group, seven of which were males. The mean age in that group was 6.1 ± 2.52 years, and the mean weight of the
animals was 5.1 ± 2.04 kg. The group included three European Shorthair cats, two Maine Coons and one British Shorthair, Persian cat and Devon Rex each. There was no statistically significant difference between the age and the weight of the animals between the groups. The results of the complete blood count and serum biochemistry are presented in Table 1, and the cardiologic parameters are presented in Table 2.

The activity of superoxide dismutase (SOD) was statistically significantly lower in animals with symptomatic and asymptomatic hypertrophic cardiomyopathy (HCM 0.99 ± 0.35 U/mL; SUB-HCM 1.39 ± 0.4 U/mL) compared to healthy cats (2.07 ± 0.76 U/mL, \( p < 0.01 \)). The activity of catalase (CAT) was significantly lower in animals at a pre-clinical stage of the disease (SUB-HCM; 19.4 ± 4.2 nmol/min/μL) and lower in symptomatic animals (HCM; 23.6 ± 5.9 nmol/min/μL, \( p < 0.01 \)), even though the latter difference was not statistically significant. The activity of glutathione peroxidase (GPx) was 4196 ± 353 nmol/min/mL in the HCM group, 4331 ± 451 nmol/min/mL in the SUB-HCM group and 4037 ± 341 nmol/min/mL in the control group and did not differ significantly between groups. The total antioxidant capacity of plasma was 602 ± 65.5 CRE in the HCM group, 605.9 ± 39.9 CRE in the SUB-HCM group and 629 ± 77.5 CRE in the healthy group, did not differ significantly between groups. In addition, there was no statistically significant difference between the groups in terms of the degree of lipid peroxidation – the concentration of malondialdehyde in blood serum was 4.07 ± 0.73 μM in the HCM, 3.84 ± 0.6 μM in the SUB-HCM group and 3.86 ± 0.71 μM MDA in the group of healthy animals.

The group of cats diagnosed with hypertrophic cardiomyopathy was subdivided into animals undergoing pharmacological treatment for the underlying medical condition (\( n = 9 \)) and animals without cardiologic treatment (\( n = 10 \)). The detailed characteristics of the pharmacological therapy are presented in Table 3. However, there were no statistically significant differences in the oxidative stress parameters in these subgroups.

Spearman correlation analysis found a significant moderate relationship between the activities of SOD and CAT (\( r = 0.44, p < 0.05 \)).

**Discussion**

This study assessed whether increased oxidative stress was a feature of symptomatic and asymptomatic hypertrophic cardiomyopathy. Oxidative stress has numerous studies been used in felines and was discovered to be involved in pathogenesis of chronic renal failure [23], diabetes mellitus [24], feline infectious peritonitis [25] and immunodeficiency virus infection [26]. To the authors’ best knowledge, this is the first study that assesses blood parameters of oxidative stress in feline hypertrophic cardiomyopathy.

The activity of superoxide dismutase and catalase in the blood serum of the studied cats showed statistically significant differences between the groups. The serum activity of superoxide dismutase was significantly lower in the group of animals diagnosed with hypertrophic cardiomyopathy. This enzyme is an important

---

**Table 1** The results of the full blood count, blood biochemistry and hormone parameters of the studied animals divided into study groups

| Variable       | HCM             | SUB-HCM         | Control         | \( p \) value |
|----------------|-----------------|-----------------|-----------------|--------------|
| WBC [K/μL]     | 7.1 (5.17–13.99)| 6.08 (4.08–18.94)| 6.72 (4.28–10.69)| 0.67         |
| RBC [M/μL]     | 9.04 (6.1–10.9) | 9.31 (7.82–10.75)| 9.42 (6.94–12.25)| 0.71         |
| HGB [g/dL]     | 13.75 (8.7–15.2)| 13.35 (11.8–15.5)| 14.6 (12.1–17.3) | 0.44         |
| HCT [%]        | 45.2 (26.5–51.8)| 45.2 (39.7–49.4) | 43.2 (36–64.1)  | 0.82         |
| AST [U/L]      | 40.5 (32–56)    | 28 (15–47)<sub>HCM</sub> | 22 (17–39)<sub>HCM</sub> | 0.003        |
| ALT [U/L]      | 63.5 (44–143)   | 58 (35–130)<sub>Controls</sub> | 42 (17–39)<sub>HCM, SUB-HCM</sub> | 0.003        |
| Urea [mmol/L]  | 9.95 (6.8–10.9) | 7.9 (5–13.4)    | 7.7 (7–9.2)     | 0.31         |
| CREA [μmol/L]  | 156.5 (95–189)  | 141 (52–222)    | 156 (106–206)   | 0.8          |
| Mg [mmol/L]    | 0.95 (0.7–102)  | 0.81 (0.64–0.91)| 0.81 (0.62–0.99)| 0.0573       |
| Na⁺ [mmol/L]   | 152.3 (150.7–163.1)| 151.7 (146.2–160.4)| 153.2 (148.9–158.7)| 0.47         |
| K [mmol/L]     | 4.17 (3.42–4.93)| 3.93 (3.11–4.36)| 4.17 (3.73–4.75)| 0.1          |
| Cl⁻ [mmol/L]   | 116.5 (113.6–116.6)| 117.5 (111.1–122.9)| 118.5 (115.2–120.7)| 0.22         |
| Ca²⁺ [mmol/L]  | 1.23 (1.19–1.33)| 1.25 (1.1–1.76) | 1.27 (1.09–1.61) | 0.51         |
| glucose [mmol/L]| 6.9 (4.5–11.9)| 7.1 (5.7–15.1) | 6.2 (4.6–13.8) | 0.55         |
| total T4 [nmol/L]| 22.08 (12.87–38.65)| 26.93 (16.94–39.32)| 30.73 (18.62–35.98)| 0.3          |

Data are presented as median (range)
component of the antioxidative enzyme system responsible for converting the superoxide radical anion (O2−) into H2O2, while one of its isoforms (SOD3) is present in blood serum [27]. This result is consistent with the findings of the study assessing a canine experimental model of heart failure caused by a surgically induced mitral valve insufficiency, where the activity of SOD in the left ventricular tissue was significantly lower in the studied animals than in the control group [28]. The results of studies on humans are divergent. The study assessing the extracellular SOD isoform in patients with cardiovascular disease of various origin [29] found that its activity was significantly lower compared to healthy controls, while this activity was significantly greater in patients with an acute coronary episode [30]. This may be explained by sudden periodic activation of the antioxidant enzyme system caused by acute ischemia. Interestingly however, cats with chronic renal failure had the same SOD activity measured in erythrocyte lysate as healthy controls [23]. Hence, the activity of this enzyme may also be a sensitive indicator of oxidative stress in cats with cardiovascular disease. Catalase is one of the main antioxidative enzymes that catalyses the breakdown of H2O2, which is most active in erythrocytes and hepatocytes, although its antioxidant activity has also been described in blood serum [31, 32]. The activity of this enzyme was significantly lower in animals at a preclinical stage of the disease and lower in symptomatic animals, even though the latter difference was not statistically significant. In veterinary medicine, the activity of this enzyme in cardiovascular disease has not been studied. Human studies have found that the serum catalase activity gradually decreases with an increase in the number of diseases vessels [33].

This is partly compliant with the results of this study. The significant decrease in the catalase activity in the asymptomatic stage of the disease may be explained by the depletion of the anti-free radical protection mechanisms, while its increased activity in the symptomatic stage of cardiovascular disease may be caused by an activation of compensatory mechanisms in response to heart failure and excessive oxidative stress. Glutathione peroxidase is an antioxidative enzyme mainly involved in the detoxification of hydrogen peroxide, and one of its isoforms (GPx3) is present in blood serum [34]. In human medicine, its activity has been studied in the blood serum of cardiologic patients and was reported to be increased [35], decreased [36–38] or statistically unchanged [39, 40] compared to the other studied groups. Interestingly, in cats glutathione peroxidase concentrations were found to be significantly increased in the course of acute feline immunodeficiency virus infection [26]. This discrepancy may suggest disease-specific changes in the activity of this enzyme, as well as variations dependent on the methodology or the study design. The results of this study suggest that the extracellular GPx isoform may not be sensitive enough as a marker of oxidative stress in cats with hypertrophic cardiomyopathy, and examining its activity in other

### Table 2: Echocardiographic parameters and the blood pressure of the studied animals divided into study groups

| Variable                  | HCM          | SUB-HCM      | Control      | p value |
|---------------------------|--------------|--------------|--------------|---------|
| total number              | 8            | 11           | 11           |         |
| LA/Ao                     | 2.42 (1.42–4.53) \(^{\text{Controls}}\) | 1.6 (1.25–1.96) \(^{\text{Controls}}\) | 1.3 (0.88–1.48) \(^{\text{HCM, SUB-HCM}}\) | .0001   |
| LVIDd                     | 14 (9–23.6)  | 12.8 (10.1–17.5) | 13.9 (12.4–20.3) | .3      |
| IVSd                      | 6.9 (4.4–8.8) \(^{\text{Controls}}\) | 6.1 (3.9–7.5) \(^{\text{Controls}}\) | 4.2 (3–5.3) \(^{\text{HCM, SUB-HCM}}\) | .0002   |
| LVDPd                     | 7.65 (4.9–8.3) \(^{\text{Controls}}\) | 5.8 (3.7–7.4) | 4 (2.9–5.6) \(^{\text{HCM}}\) | .0014   |
| LVIDs                     | 6.1 (2.2–12.8) | 5.3 (3.6–9.1) | 8.1 (5.4–11.3) | .07     |
| IVSs                      | 8.55 (5.8–10.2) | 7.5 (5.7–9.3) | 7 (5.3–9.3) | .36     |
| LVPWs                     | 9.95 (7.4–13.4) \(^{\text{Controls}}\) | 8.1 (6.4–10.5) | 6.4 (5.1–9.6) \(^{\text{HCM}}\) | .0012   |
| LVOTO                     | 4/8          | 0/11         | 0/11         | .04     |
| HR                        | 203 (162–265) | 222 (136–285) | 214 (154–234) | .52     |
| SAP [mmHg]                | 110 (95–136) \(^{\text{SUB-HCM}}\) | 139 (110–146) \(^{\text{HCM}}\) | 128 (90–150) | .03     |

Data are presented as median (range). Abbreviations: LA/Ao left atrium to aorta ratio, LVIDd left ventricular inner diameter in diastole, IVSd intraventricular septum in diastole, LVOTO left ventricular outflow tract obstruction, HR heart rate, SAP systolic arterial pressure. M-Mode heart dimensions were measured in the subvalvular region.
It has been found that numerous drugs used to treat hypertrophic cardiomyopathy, such as ACE inhibitors, beta-blockers and calcium channel blockers, may have antioxidant effects [54–56]. Contrary to our expectations, we did not find statistically significant differences in any of the oxidative stress parameters between cats without treatment and those in the course of pharmacological therapy. This result is consistent with the findings in dogs with cardiovascular disease [45]. The groups in the current study were small, and the pharmacotherapy was tailored to the patient needs and differed between individuals. In addition, the current study was not specifically designed to assess this matter, which may have affected the results.

Our study had some limitations. It is clear that small sample size is a major limitation of our study. In future studies, this number should be higher in order to extrapolate to a larger population. The impact of the diet of the studied animals on the oxidative stress parameters cannot be ruled out. However, all the cats were fed commercial feline diets. The body score was not assessed when including the cats in the study although evidently obese or thin individuals were excluded from it. No uniform pharmacological therapy of the animals was another major study limitation.

Conclusions
In conclusion, the results indicate that the activities of superoxide dismutase and catalase are different in cats with hypertrophic cardiomyopathy, however the activity of the latter was only lower in asymptomatic stage of the disease. However, further studies assessing other markers of oxidative stress and using other biological tissues of cats with hypertrophic cardiomyopathy are warranted. In addition, the potentially beneficial effect of antioxidative substances on the disease progression in the asymptomatic and symptomatic stage of this disease should also be examined.

Methods
Animals
This observational, cross-sectional study was performed with 30 cats that were divided into two groups: hypertrophic cardiomyopathy and control group. Before enrolling an animal into the study, a written consent for a full cardiac examination and blood sampling was obtained from the owner. The cats remained under the care of their owners during and after the study.

All cats included in the study underwent a clinical examination, a six-lead electrocardiogram (BTL-08, BTL Industries, U.K.), a standard transthoracic echocardiography (Aloka F36 or Aloka Arietta V60, Hitachi-Aloka, Tokyo, Japan), and a non-invasive blood pressure measurement using the Doppler ultrasonic method (Parks...
Transthoracic echocardiography was performed by experienced echocardiographers (UP and ANN) using an echocardiograph equipped with a 3–14 MHz sector, phased-array transducer. The LA/Ao ratio and M-mode echocardiography measurements were performed using the right parasternal short-axis view. Hypertrophic cardiomyopathy was diagnosed when M-Mode derived IVSd and/or LVPWd measurements were ≥ 6 mm [1]. Diagnosis of hypertrophic obstructive cardiomyopathy was made by the presence of left ventricular hypertrophy together with one of the following signs: systolic anterior motion of the mitral valve leaflet noted on M-mode echocardiography, mitral valve regurgitant flow and dynamic left ventricular outflow tract obstruction evident on color flow Doppler echocardiography and/or an increased peak with a dagger-shaped spectrum in the left ventricular outflow tract velocity apparent on continuous wave Doppler echocardiography [57].

Blood pressure measurement
Systolic arterial blood pressure measurement was taken using a noninvasive Doppler method and a standardized ISFM protocol was adhered to [58]. Measurements were taken in a calm and quiet environment with only owner and experienced examiner present and away from other animals. All cats were allowed to acclimatise for a minimum of 5 min. An appropriately sized inflatable cuff was placed around forelimb and at least 6 measurements were taken. Systolic blood pressure was calculated as mean of several consistent readings.

Blood analyses
Blood samples were collected from the cephalic vein into plain and lithium heparin tubes as a part of the cardiac examination. Blood collected into plain tubes was left to clot for 15 min in room temperature and was then centrifuged at 2000 x g at 4 °C for 15 min, while blood collected into lithium heparin tubes was centrifuged immediately after collection in the same conditions. To avoid the influence of leukocytes or red blood cells antioxidant enzymes activity, plasma and serum were collected from top layer without disturbing a buffy coat layer. Plasma and serum was transferred to an analytical laboratory for basic laboratory tests, while the remaining material was divided and immediately frozen at −80 °C until analysis. All enzymatic tests were assayed within 4 weeks of sample collection. Laboratory tests included haematology and biochemical analysis: alanine transaminase (ALT), aspartate transaminase (AST), urea, creatinine, glucose, total thyroxine (T4) and ionogram (Mg²⁺, Cl⁻, K⁺, Na⁺, Ca²⁺).

Determination of sera antioxidant enzymes activity
Superoxide dismutase The serum activity of CuZn-SOD was determined using a commercially available
Catalase
The activity of serum catalase was measured using a commercially available kit (Cayman Chemical; 707002). Because erythrocytes are rich in CAT, serum samples have been prepared with high precision and have not been used if any signs of haemolysis was observed. Assay serum dilution was tested and validated in the same way as for superoxide dismutase. Intra-assay coefficient of variation of undiluted serum was 20%. We used undiluted serum to run the assay in accordance with the manufacturer’s instruction. Feline serum exhibited a linear relationship between the amount of sample and CAT activity over a wide range. One unit was defined as the amount of enzyme needed to elicit 50% dismutation of the superoxide anion radical.

Glutathione peroxidase
The plasma glutathione peroxidase enzyme assay was carried out according to the Paglia and Valentine method using Cayman’s assay kit (Cayman Chemical; 703102). The plasma dilution was validated and intra-coefficient of variation was calculated (7.65%). Samples were diluted 1:2 in sample buffer provided by producer. Activity of enzyme was calculated as a change in absorbance during one minute. GPx activity was calculated using a formula:

\[
GPX \text{ activity} = \frac{\Delta A_{340}}{0.00373 \mu M^{-1} \cdot 0.19 \text{ ml}^{-2} \cdot 2 \text{ min}^{-1}} = \frac{nmol}{ml}
\]

One unit of activity was defined as the amount of enzyme causing the formation of 1 nmol of formaldehyde per minute at room temperature.

Determination of plasma total antioxidant capacity
The total antioxidant capacity in the heparinized plasma was determined using the OxiSelect Total Antioxidant Capacity assay kit (Cell Biolabs Inc., San Diego, CA, USA). Test was validated for feline plasma and intra-coefficient of variation was calculated (5.7%). The result was calculated and the total sample antioxidant power was expressed as copper reducing equivalents (CRE).

Determination of total malondialdehyde in plasma (MDA)
Lipid peroxidation levels in the heparinized plasma were assessed by measuring malondialdehyde (MDA) formation using the Bioxytech MDA-586 kit (Oxis Research, Portland, OR, USA). Precision of the test for feline plasma was 16.7%. Undiluted samples were prepared following the instructions of the manufacturer. To prevent further sample oxidation, the hydrolysis of the samples was performed in the presence of butylated hydroxytoluene). The results are shown as the concentration of MDA in the sample, expressed in μM.

The absorbance of the products of all the enzymatic reactions were measured spectrophotometrically using a microplate reader (Tecan Spark 10 M, Tecan, Austria). All the samples were assayed in the same assay run in duplicate and analysed simultaneously by one examiner (AT), who was blinded to the sample origin, while the final result was an average value of two measurements.

Statistical methods
All the collected data was subjected to statistical analysis using GraphPad Prism 5.0 software. The D’Agostino and Pearson normality test were used to assess the distribution of the data. Depending on the results, the groups were compared using the one-way ANOVA with Bonferroni post-hoc test or the Kruskal-Wallis with the post-hoc Dunns analysis. An unpaired t-test or the Mann-Whitney test were used to compare two sets of variables, depending on the data distribution. The correlation between the groups of variables was determined using the Spearman correlation coefficient. Statistical significance was set at \( p \leq 0.05 \).

Abbreviations
ALT: Alanine transaminase; AST: Aspartate transaminase; ATE: Arterial thromboembolism; CAT: Catalase; CRE: Copper reducing equivalents; GPx: Glutathione peroxidase; HCM: Hypertrophic cardiomyopathy; MDA: Malondialdehyde; ROS: Reactive oxygen species; SOD: Superoxide dismutase; T4: Thyroxine; TAC: Total antioxidant capacity

Acknowledgements
Not applicable.

Authors’ contributions
MM designed the study, collected, interpreted and analyzed the patient and biochemical data, a major contributor in writing the manuscript; AT performed the biochemical analysis; UP collected, interpreted and analyzed the patient data; ANN designed the study, collected, interpreted and analyzed the patient and biochemical data, contributed in writing the manuscript. All authors read and approved the final manuscript.
Presenting to University Blood samples used as controls were collected from healthy animals examination. Owner and a high standard of care was adhered to throughout each for a full cardiac examination and blood sampling was obtained from the necessary. However, before enrolling a cat into the study, a written consent analyses was taken during a routine veterinary examination and in accordance with the above mentioned legal act, a written ethical approval from the Local Ethical Committee before beginning the study was not necessary. However, before enrolling a cat into the study, a written consent for a full cardiac examination and blood sampling was obtained from the owner and a high standard of care was adhered to throughout each examination. Blood samples used as controls were collected from healthy animals presenting to University’s Small Animal Veterinary Practice for preventive screening. Additional cardiac examination was offered to these individuals at no further cost.

Consent for publication Not applicable.

Competing interests The authors declare that they have no competing interests.

Author details
1. Department of Veterinary Medicine and Clinic of Diseases of Horses, Dogs and Cats, Faculty of Veterinary Medicine, Wrocław University of Environmental and Life Sciences, Grunwaldzki sq. 47, Wrocław 50-366, Poland.
2. Department of Food Hygiene and Consumer Health, Faculty of Veterinary Medicine, Wrocław University of Environmental and Life Sciences, Cr. Norwida 31, Wrocław 50-375, Poland.

Received: 13 October 2018 Accepted: 23 January 2020

Published online: 30 January 2020

References
1. Ferarison L, Sturgess CP, Cannon MJ, Caney SM, Gruffydd-Jones TJ, Wotton PR. Feline idiopathic cardiomyopathy: a retrospective study of 106 cats (1994-2001). J Feline Med Surg. 2003;5(3):151–9.
2. Payne JR, Borget K, Connolly DJ, Boswood A, Dennis S, Wagner T, et al. Prognostic indicators in cats with preclinical hypertrophic cardiomyopathy. J Vet Intern Med. 2011;27(6):1427–36.
3. Fox PK, Keene BW, Lamb K, Schober KA, Chetboul V, Luis Fuentes V, et al. International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: the REVEAL study. J Vet Intern Med. 2016;32(6):1309–10.
4. Kittleson MD, Meurs KM, Munro MJ, Kittleson JA, Liu SK, Pion PD, Towbin JA. Familial hypertrophic cardiomyopathy in Maine coon cats: an animal model of human disease. Circulation. 1999;99(24):1372–80.
5. Meurs KM, Nisgard MM, Edler MM, Hendrix KP, Kittleson MD. A substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy. Genomics. 2007;90(2):261–4.
6. Gianström S, Godilken MT, Christansen M, Pippper CB, Willesen JL, Koch J. Prevalence of hypertrophic cardiomyopathy in a cohort of British shorthair cats in Denmark. J Vet Intern Med. 2011;25(4):866–71.
7. März I, Wilkie LJ, Harrington N, Payne JR, Muzzi RA, Hägglöström J, et al. Familial cardiomyopathy in Norwegian Forest cats. J Feline Med Surg. 2015;17(8):681–91.
8. Meurs KM, Sanchez X, David RM, Bowles NE, Towbin JA, Reiser PJ, et al. A cardiac myosin binding protein C mutation in the Maine coon cat with familial hypertrophic cardiomyopathy. Hum Mol Genet. 2005;14:3587–93.
9. Luis Fuentes V, Wilkie LJ. Asymptomatic hypertrophic cardiomyopathy: diagnosis and therapy. Vet Clin North Am Small Anim Pract. 2017;45(5):1041–54.
10. Rishniv M, Pion PD. Is treatment of feline hypertrophic cardiomyopathy based in science or faith? A survey of cardiologists and a literature search. J Feline Med Surg. 2011;13(7):487–97.
11. Green EM, Wakimoto H, Anderson RL, Evanicki MJ, Gorham JM, Harrison BC, et al. A small-molecule inhibitor of sarco-mer contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351(6273):617–21.
12. Stern JA, Markova S, Ueda Y, Kim JB, Pascoe PJ, Evanicki MJ, et al. A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy. PLoS One. 2016;11(12):e0168407.
13. Ahmed Z, Tang WH. Pharmacologic strategies to target oxidative stress in heart failure. Curr Heart Fail Rep. 2012;9(1):14–22.
14. Yang HY, Lee TH. Antioxidant enzymes as redox-based biomarkers: a brief review. BMB Rep. 2015;48(4):200–8.
15. Jain AK, Mehta NK, Swarnakar NK. Role of antioxidants for the treatment of cardiovascular diseases: challenges and opportunities. Curr Pharm Des. 2015;21(30):4441–55.
16. Liu T, Korantzopoulos P, Li G. Antioxidant therapies for the management of atrial fibrillation. Cardiovasc Diagn Ther. 2012;2(4):298–307.
17. Sini HN, Kambilash Y, Kambilash J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vasc Pharmacol. 2015;71:40–56.
18. Tsutsui H, Kinugawa S, Matsusima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301(6):H2181–90.
19. Steinberg SF. Oxidative stress and sarcornic proteins. Circ Res. 2013;112:393–405.
20. Dimitrow PP, Undas A, Wolkow P, Tracz W, Dubiel JS. Enhanced oxidative stress in hypertrophic cardiomyopathy. Pharmacol Rep. 2009;61(3):491–5.
21. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol. 1996;28(2):506–14.
22. Christansen LB, Deia F, Koch J, Hansen CN, Leifson PS, Yokota T. Impaired cardiac mitochondrial oxidative phosphorylation and enhanced mitochondrial oxidative stress in feline hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2015;308(1H):1237–47.
23. Keegan RF, Webb CB. Oxidative stress and neutrophil function in cats with chronic renal failure. J Vet Intern Med. 2010;24(3):514–9.
24. Webb CB, Failkowski L. Oxidative stress and innate immunity in feline patients with diabetes mellitus: the role of nutrition. J Feline Med Surg. 2009;11(4):271–6.
25. Tecles F, Càldin M, Tvarionavičius A, Escrnado B, Martínez-Sabiela S, Cerdón JJ. Serum biomarkers of oxidative stress in cats with feline infectious peritonitis. Vet Res Sci. 2015;100:12–7.
26. Webb C, Lehman T, McCord K, Avey P, Dow S. Oxidative stress during acute FIV infection in cats. Vet Immunol Immunopathol. 2008;122(1–2):16–24.
27. Marklund SL. Human copper-containing superoxide dismutase of high molecular weight. Proc Natl Acad Sci U S A. 1982;79(24):7634–8.
28. Prasad K, Gupta JB, Kalfa J, Lee P, Manthu SY, Bhardwaj B. Oxidative stress as a mechanism of cardiac failure in chronic volume overload in canine model. J Mol Cell Cardiol. 1996;28(3):375–85.
29. Yang J, Lee JH, Cho EY, Chung NS, Topham D, Balderston B. Differences in body fat distribution and antioxidant status in Korean men with cardiovascular disease with or without diabetes. Am J Clin Nutr. 2001;73(1):68–74.
30. Jain AP, Mohan A, Gupta OP, Jajoo UN, Kalantri SP, Srivastava LM. Role of oxygen free radicals in causing endothelial damage in acute myocardial infarction. J Assoc Physicians India. 2000;48(5):478–80.
31. Kodykciok J, Vávrová L, Kocík M, Vávrová L, Kocík M, Vádrová L. Antioxidant therapies for the management of atrial fibrillation. Cardiovasc Diagn Ther. 2012;2(4):298–307.
32. Leff JA, Oppegard MA, Terada LS, McCarty EC, Repine JE. Human serum catalase decreases endothelial cell injury from hydrogen peroxide. J Appl Physiol. 1985;1991;71(5):1903–6.
33. Serdar Z, Aslan K, Dirican M, Sarandol E, Yesilbursa D, Serdar A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clin Biochem. 2006;39(8):794–803.

34. Brigellus-Flohé R, Maierino M. Glutathione peroxidases. Biochim Biophys Acta. 2013;1830(5):3289–303.

35. Zachara BA, Ukleja-Adamowicz M, Nartowicz E, Lecka J. Increased plasma glutathione peroxidase activity in patients with acute myocardial infarction. Med Sci Monit. 2001;7(3):415–20.

36. Porter M, Pearson DJ, Suarez-Mendez VJ, Blann AD. Plasma, platelet and erythrocyte glutathione peroxidases as risk factors in ischaemic heart disease in man. Clin Sci (Lond). 1992;83(3):343–5.

37. Blann AD, Maxwell SR, Bunows G, Miller JP. Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolaemia and vascular disease. Atherosclerosis. 1995;116(2):191–8.

38. Domínguez-Rodríguez A, Abreu-González P, García MJ, Sanchez J, Marrero F, de Armas-Trujillo D. Decreased nocturnal melatonin levels during acute myocardial infarction. J Pineal Res. 2002;33(4):248–52.

39. Dubois-Randé JL, Artigou JY, Darmon JY, Habbal R, Manuel C, Tayarani I, Castaigne A, Grosgeay Y. Oxidative stress in patients with unstable angina. Eur Heart J. 1994;15(2):179–83.

40. Rajasekhar D, Srinivasa Rao PV, Latheef SA, Saibaba KS, Subramanyam G. Association of serum antioxidants and risk of coronary heart disease in south Indian population. Indian J Med Sci. 2004;58(11):465–71.

41. Serdar A, Yesilbursa D, Serdar Z, Dirican M, Turel B, Cordan J. Relation of functional capacity with the oxidative stress and antioxidants in chronic heart failure. Congest Heart Fail. 2001;7(6):309–13.

42. Pollidori MC, Savino K, Alunni G, Freddio M, Senin U, Sies H, et al. Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: relationship to disease severity. Free Radic Biol Med. 2002;32(2):148–52.

43. Díaz-Vélez CR, García-Castilleiras S, Mendoza-Ramos E, Hernández-López E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J. 1996;131(1):146–52.

44. Freeman LM, Brown DJ, Rush JE. Assessment of degree of oxidative stress and antioxidant concentrations in dogs with idiopathic dilated cardiomyopathy. J Am Vet Med Assoc. 1999;215(5):644–6.

45. Verk B, Nemec Svete A, Salobir J, Rezar V, Domanjko PA. Markers of oxidative stress in dogs with heart failure. J Vet Diagn Invest. 2017;29(5):636–44.

46. Freeman LM, Rush JE, Milbury PE, Blumberg JB. Antioxidant status and biomarkers of oxidative stress in dogs with congestive heart failure. J Vet Intern Med. 2005;19(4):537–41.

47. Tingberg E, Ohiin AK, Gottstätter A, Ohiin H. Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy. Int J Cardiol. 2006;112(3):275–81.

48. Halliwell B. Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward? Cardiovasc Res. 2000;47(3):410–20.

49. Apak R, Güçlü K, Ozyürek M, Karademir SE, Altun M. Total antioxidant glutathione peroxidase activity in patients with acute myocardial infarction. Med Sci Monit. 2001;7(3):415–20.

50. Porter M, Pearson DJ, Suarez-Mendez VJ, Blann AD. Plasma, platelet and erythrocyte glutathione peroxidases as risk factors in ischaemic heart disease in man. Clin Sci (Lond). 1992;83(3):343–5.

51. Campos C, Guzmán R, López-Fernández E, Casado A. Evaluation of the antioxidant and protein oxidation status in patients with angiographically proven coronary artery disease. Clin Biochem. 2006;39(8):794–803.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.